RU97113694A - APPLICATION OF 3,4-DIPHENYLCHROMANES FOR OBTAINING A PHARMACEUTICAL COMPOSITION FOR VASCULATING TREATMENT OR PREVENTION - Google Patents

Claims (22)

1. The use of compounds of General formula I

in which R ¹ , R ⁴ and R ⁵ individually represent hydrogen, hydroxy, halogen, trifluoromethyl, lower alkyl, lower alkoxy or (tertiary amino) (lower alkoxy); R ² and R ³ are individually hydrogen or lower alkyl, or in the form of their pharmaceutically acceptable salt in combination with a pharmaceutically acceptable carrier for preparing a pharmaceutical composition exhibiting a vasodilating effect.  2. The use according to claim 1 for treating or preventing cerebral ischemia.  3. The use according to claim 1 for the treatment or prevention of angina.  4. The use of claim 1 for treating or preventing Raynaud's syndrome. 5. Application according to any one of paragraphs. 1-4, in which the specified compound has the General formula III

in which R ¹ , R ² , R ³ , R ⁴ and R ⁵ each has the meaning given in paragraph 1. 6. Application according to any one of the preceding paragraphs. 1-5, in which R ¹ represents lower alkoxy, preferably methoxy. 7. The use according to any one of the preceding paragraphs, in which R ² represents lower alkyl, preferably methyl. 8. The use according to any one of the preceding paragraphs, in which R ³ represents lower alkyl, preferably methyl. 9. The use according to any one of the preceding paragraphs, in which R ⁴ represents hydrogen. 10. The use according to any one of the preceding claims, wherein R ⁵ is (tertiary amino) (lower alkoxy), preferably 2- (pyrrolidin-1-yl) ethoxy.  11. The use according to any one of the preceding claims, wherein said compound is a stereoisomer, for example, an isolated d or l-enantiomer.  12. The use according to any one of the preceding claims, wherein said compound is an isolated d-enantiomer.  13. Application according to any one of the preceding paragraphs. 1-4, in which the specified connection is a 3,4-TRANS-2,2-dimethyl-3-phenyl-4- [4- (2-pyrrolidin-1-yl) ethoxy) phenyl] -7-methoxychroman.  14. The use according to the preceding paragraph, wherein said compound is an isolated d- or 1-enantiomer of 3,4-trans-2,2-dimethyl-3-phenyl-4- [4- (2-pyrrolidin-1-yl) ethoxy) phenyl] -7-methoxychroman.  15. The use according to claim 14, wherein said compound is d-3,4-trans-2,2-dimethyl-3-phenyl-4- [4- (2-pyrrolidin-1-yl) ethoxy) phenyl] -7-methoxychroman.  16. The use according to any one of the preceding claims, wherein said composition is in a form suitable for oral administration.  17. The use according to any one of the preceding claims, wherein said compound is administered as a dose in the range of from about 0.001 to 75, preferably in the range of from about 0.01 to 75, more preferably in the range of from about 0.01 to 50 and especially in the range of approximately 0.1 to 25 mg / kg of patient per day.  18. The use according to any one of the preceding claims, wherein said compound is administered one or more times a day or a week.  19. The use according to any one of the preceding paragraphs, in which said composition is in the form of a dermal implant.  20. A method of vasodilator treatment and prophylaxis, for example, cerebral ischemia, angina pectoris or Raynaud's syndrome, comprising administering to a patient a therapeutically effective amount of compounds of formula I, as stated for use in any of the preceding points of use, or their pharmaceutically acceptable salts.  21. A method of vasodilator treatment or prophylaxis, for example, cerebral ischemia, angina pectoris or Raynaud’s syndrome, the method comprising administering a therapeutically effective amount of a compound of formula I or its salt and pharmaceutically acceptable compositions containing such a compound to a patient in need of such treatment.  22. Any new feature or combination of features described here.